RxDoctor Payments Data

Windsen Pan, MD

Internal Medicine · Houston, TXNPI 1710286935

Payments from drug & device makers

$2,156in general payments, 2019–2025

Across 116 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$625
  • GSK$230
  • AbbVie$175
  • Pfizer$163
  • Lilly USA, LLC$126
  • AstraZeneca$116
  • plus $721 from 18 others

What the payments were for

  • Food & beverage$2,156100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,156 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,113
Medicare patients
280
Services billed
1,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$92,079
MounjaroTirzepatide26$52,368
JardianceEmpagliflozin25$38,099
JanuviaSitagliptin Phosphate20$29,665
RybelsusSemaglutide16$27,215
Tresiba Flextouch U-100Insulin Degludec11$26,669
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$20,980
Synjardy XrEmpagliflozin/Metformin Hcl16$13,557
Advair HfaFluticasone Propion/Salmeterol11$5,728
Rosuvastatin Calcium319$5,236
SymbicortBudesonide/Formoterol Fumarate18$4,656
Atorvastatin Calcium406$4,265
Albuterol Sulfate HfaAlbuterol Sulfate81$2,890
SynthroidLevothyroxine Sodium56$2,845
Levothyroxine Sodium251$2,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$625$119,29487 claims
Lilly USA, LLCMounjaro$126$52,36826 claims
Boehringer IngelheimJardiance, Synjardy Xr$21$51,65641 claims
GSKTrelegy Ellipta$230$20,98024 claims
AstraZenecaSymbicort$116$4,65618 claims
AbbVieSynthroid$175$2,84556 claims
PfizerPaxlovid$163$1,42927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →